Filing Flows › Arcutis Biotherapeutics (ARQT) › Q2 2025
Arcutis Biotherapeutics (ARQT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Arcutis Biotherapeutics (ARQT) reported revenue of $81.5M for the second quarter 2025 (Q2 2025), +164% from a year earlier and +24% from the quarter before. Operating margin was -17.9%, net loss $15.9M (19.5% of revenue).
Arcutis Biotherapeutics, Q2 2025: revenue $81.5M (+164% year over year), operating margin -17.9%, net loss $15.9M, operating cash flow $324K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $81.5M | +24% | +164% |
| Operating profit | −$14.6M | — | — |
| Net earnings | −$15.9M | — | — |
| Operating cash flow | $324K | — | — |
| Free cash flow | $246K | — | — |
What changed
Revenue was $81.5M in Q2 2025, up 164% year over year and up 24% from the previous quarter. ZORYVE foam was the largest line at 48% of revenue. ZORYVE foam added $25.6M year over year (up 188%), 51% of the total change.
Operating costs exceeded revenue by $14.6M, an operating margin of -17.9%. Total costs grew 19% against revenue growth of 164%. The fastest-growing cost line was Cost of revenue (+116%). The quarter ended with a net loss of $15.9M, narrower than the previous quarter's $25.1M loss.
Operating cash flow was $324K. Non-cash charges added back $10.5M of share-based compensation. Working capital and other items added $5.7M. Capital expenditures of $78K left free cash flow of $246K.
Questions
What was Arcutis Biotherapeutics' revenue in the second quarter 2025?
Arcutis Biotherapeutics (ARQT) reported revenue of $81.5M for the second quarter 2025 (Q2 2025), +164% from a year earlier and +24% from the quarter before.
Was Arcutis Biotherapeutics profitable in the second quarter 2025?
Operating loss was $14.6M (-17.9% of revenue) and net loss $15.9M.